Study on IV Ganaxolone for Refractory Status Epilepticus

In individuals with refractory status epilepticus (RSE), IV ganaxolone quickly and effectively controlled their seizures while also demonstrating acceptable safety and tolerability, says an article published in Epilepsia.

One second-line IV anti-seizure medicine (ASM) and benzodiazepines have not been effective in treating patients with refractory status epilepticus. When second-line ASMs are ineffective, guidelines advise IV anesthesia, but possible risks may exceed the advantages. To halt and permanently manage RSE without resorting to IV anesthetics, novel therapies are required. An experimental neuroactive steroid being developed for the treatment of RSE is called ganaxolone. The purpose of this study, which was carried out by Henrikas Vaitkevicius and colleagues, was to establish the ideal IV ganaxolone dosage for RSE and to gain a preliminary evaluation of effectiveness and safety.

From February 19, 2018, until September 18, 2019, three locations in the United States hosted an open-label, phase 2 study. Patients who experienced convulsive or non-convulsive SE were under the age of 12 and did not improve after receiving one second-line IV ASM. 21 patients were screened, and 17 were accepted. Patients got standard-of-care ASMs with IV ganaxolone added. An IV bolus of ganaxolone was used to start the infusion, which continued at decreasing infusion rates for 48–96 hours until tapering down for 18 hours. Three ganaxolone dosage cohorts were used: low (500 mg/day), medium (650 mg/day), and high (713 mg/day). The number of patients who did not require escalation to IV anesthesia within 24 hours of ganaxolone induction was the primary end objective.

Key Findings of the Study

• The majority of the 17 patients who were included (65%) had non-convulsive SE and had tried a median of three prior ASMs, including first- and second-line IV ASM treatment.
• The median amount of time after starting ganaxolone for SE cessation was 5 minutes.
• In the 24 hours after starting ganaxolone, no patient needed to be escalated to third-line IV anesthetics.
• Sedations were described as two treatment-related significant adverse events.
• None of the three deaths were thought to be attributable to ganaxolone and they all happened 9–22 days after the completion of the drug.

In conclusion, treatment for status epilepticus that is refractory is difficult since the illness has a high death rate. According to preliminary findings, ganaxolone therapy has promise as a possible cure for refractory status epilepticus.

Reference

Vaitkevicius, H., Ramsay, R. E., Swisher, C. B., Husain, A. M., Aimetti, A., & Gasior, M. (2022). Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open‐label, dose‐finding, phase 2 trial. In Epilepsia. Wiley. https://doi.org/10.1111/epi.17343